Oren Gilad
Algemeen Directeur bij APREA THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-05-2024
Profiel
Oren Gilad was the founder of Atrin Pharmaceuticals LLC, founded in 2011, where he held the title of President, Chief Executive Officer & Director.
He was also the founder of Atrin Pharmaceuticals, Inc., founded in 2011, where he held the title of President & Chief Executive Officer.
Currently, Mr. Gilad is the President, Chief Executive Officer & Director at Aprea Therapeutics, Inc. since 2022.
Mr. Gilad has a doctorate degree from the University of Pennsylvania, a doctorate degree from the University of California, Davis, and an undergraduate degree from The Hebrew University of Jerusalem.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
APREA THERAPEUTICS, INC.
5.90% | 23-04-2024 | 320 526 ( 5.90% ) | 2 M $ | 31-05-2024 |
Actieve functies van Oren Gilad
| Bedrijven | Functie | Begin |
|---|---|---|
| APREA THERAPEUTICS, INC. | Algemeen Directeur | 29-06-2022 |
Eerdere bekende functies van Oren Gilad
| Bedrijven | Functie | Einde |
|---|---|---|
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Oprichter | 01-01-2022 |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Algemeen Directeur | 01-01-2022 |
Opleiding van Oren Gilad
| The Hebrew University of Jerusalem | Undergraduate Degree |
| University of California, Davis | Doctorate Degree |
| University of Pennsylvania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
